Legis Daily

Increasing Access to Biosimilars Act of 2020

USA116th CongressS-4134| Senate 
| Updated: 7/1/2020
John Cornyn

John Cornyn

Republican Senator

Texas

Cosponsors (2)
Michael F. Bennet (Democratic)Tina Smith (Democratic)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Increasing Access to Biosimilars Act of 2020 This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Mar 10, 2020

Latest Companion Bill Action

HR 116-6179
Introduced in House
Jul 1, 2020
Introduced in Senate
Jul 1, 2020
Read twice and referred to the Committee on Finance.
  • March 10, 2020

    Latest Companion Bill Action

    HR 116-6179
    Introduced in House


  • July 1, 2020
    Introduced in Senate


  • July 1, 2020
    Read twice and referred to the Committee on Finance.

Health

Related Bills

  • HR 116-6179: Increasing Access to Biosimilars Act of 2020
Congressional oversightGovernment studies and investigationsHealth care costs and insuranceHealth information and medical recordsHealth programs administration and fundingMedicarePrescription drugs

Increasing Access to Biosimilars Act of 2020

USA116th CongressS-4134| Senate 
| Updated: 7/1/2020
Increasing Access to Biosimilars Act of 2020 This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Mar 10, 2020

Latest Companion Bill Action

HR 116-6179
Introduced in House
Jul 1, 2020
Introduced in Senate
Jul 1, 2020
Read twice and referred to the Committee on Finance.
  • March 10, 2020

    Latest Companion Bill Action

    HR 116-6179
    Introduced in House


  • July 1, 2020
    Introduced in Senate


  • July 1, 2020
    Read twice and referred to the Committee on Finance.
John Cornyn

John Cornyn

Republican Senator

Texas

Cosponsors (2)
Michael F. Bennet (Democratic)Tina Smith (Democratic)

Finance Committee

Health

Related Bills

  • HR 116-6179: Increasing Access to Biosimilars Act of 2020
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Congressional oversightGovernment studies and investigationsHealth care costs and insuranceHealth information and medical recordsHealth programs administration and fundingMedicarePrescription drugs